» Articles » PMID: 22820858

Expression of the E-cadherin Repressors Snail, Slug and Zeb1 in Urothelial Carcinoma of the Urinary Bladder: Relation to Stromal Fibroblast Activation and Invasive Behaviour of Carcinoma Cells

Overview
Publisher Springer
Date 2012 Jul 24
PMID 22820858
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT) is regulated by interaction of carcinoma and stromal cells and crucial for progression of urinary bladder carcinoma (UBC). Therefore, the influence of activated fibroblasts on the expression of E-cadherin repressors as well as EMT and invasion in UBC was investigated. A correlative analysis of the immunohistochemical expression of fibroblast (ASMA, S100A4, FAP, SDF1, PDGFRβ) and EMT (Snail, Slug, Zeb1, E-cadherin) markers was performed on 49 UBC cases of different stages. The impact of distinguishable growth factor stimulated fibroblasts on invasion, EMT, and E-cadherin repressor expression was investigated in an invasion model. In situ, invasiveness was significantly correlated to the loss of membranous E-cadherin (E-cad_m) and increased Snail, Slug, Zeb1 in tumour cells, as well as to increased ASMA, S100A4, and PDGFRβ in stromal cells. A significant correlation to nodal metastasis could be evidenced for the loss of E-Cad_m, and for an increase in S100A4 and PDGFRβ. Comparison of stromal and EMT markers revealed significant correlations of ASMA to Snail and Slug; of S100A4 to the loss of E-cad_m and Zeb1; and of PDGFRβ to the loss of E-Cad_m, Slug and Zeb1. In vitro, TGFβ1 induced myofibroblasts were the strongest attractants, while aFGF or TGFβ1/aFGF stimulated fibroblasts were the most potent EMT inductors. As shown here for the first time, distinct sub-populations of fibroblasts are to various extents associated with EMT and tumour progression in UBC. These relevant findings might be the basis for the identification of new diagnostic markers and therapeutic targets selectively affecting tumour supporting CAF effects.

Citing Articles

Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.

Yang T, Luo W, Yu J, Zhang H, Hu M, Tian J Front Immunol. 2024; 15:1481296.

PMID: 39559360 PMC: 11570592. DOI: 10.3389/fimmu.2024.1481296.


LncRNA MEG3 Inhibits the Epithelial-mesenchymal Transition of Bladder Cancer Cells through the Snail/E-cadherin Axis.

Wang L, Wang P, Liu B, Zhang H, Wei C, Xiong M Curr Med Sci. 2024; 44(4):726-734.

PMID: 38990449 DOI: 10.1007/s11596-024-2895-x.


Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z Int J Mol Sci. 2024; 25(10).

PMID: 38791528 PMC: 11122264. DOI: 10.3390/ijms25105490.


Characterization and verification of CAF-relevant prognostic gene signature to aid therapy in bladder cancer.

Zhou H, Li R, Liu J, Long J, Chen T Heliyon. 2024; 10(3):e23873.

PMID: 38317915 PMC: 10839800. DOI: 10.1016/j.heliyon.2023.e23873.


The role of cancer-associated fibroblasts in bladder cancer progression.

Huang L, Xie Q, Deng J, Wei W Heliyon. 2023; 9(9):e19802.

PMID: 37809511 PMC: 10559166. DOI: 10.1016/j.heliyon.2023.e19802.


References
1.
van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, HUBER H . Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009; 28(45):4022-33. PMC: 2900602. DOI: 10.1038/onc.2009.253. View

2.
Matsumoto K, Irie A, Satoh T, Ishii J, Iwabuchi K, Iwamura M . Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 2007; 70(3):602-7. DOI: 10.1016/j.urology.2007.04.007. View

3.
Wang X, Zhang K, Sun L, Liu J, Lu H . Short interfering RNA directed against Slug blocks tumor growth, metastasis formation, and vascular leakage in bladder cancer. Med Oncol. 2010; 28 Suppl 1:S413-22. DOI: 10.1007/s12032-010-9728-4. View

4.
Mighell A, Thompson J, Hume W, Markham A, Robinson P . RT-PCR investigation of fibronectin mRNA isoforms in malignant, normal and reactive oral mucosa. Oral Oncol. 1997; 33(3):155-62. DOI: 10.1016/s0964-1955(96)00074-7. View

5.
Bryan R, Tselepis C . Cadherin switching and bladder cancer. J Urol. 2010; 184(2):423-31. DOI: 10.1016/j.juro.2010.04.016. View